Drug Approval | June 27, 2023
USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Economic analysis of cost of Vall d’Hebron University Hospital Stroke Unit shows direct-to-angio stroke pathway can save more than USD 3,000 per patient
UTD2 is the world's first oral epothilone microtubule inhibitor
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Injectafer is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency
Subscribe To Our Newsletter & Stay Updated
